Pankovitch Sarah, Frohlich Michael, AlOthman Bader, Marciniuk Jeffrey, Bernier Joanie, Paul-Emile Dorcas, Bourbeau Jean, Ross Bryan A
Montreal Chest Institute, McGill University Health Centre, Montreal, QC, Canada.
Montreal Chest Institute, McGill University Health Centre, Montreal, QC, Canada; Division of Respiratory Medicine, Department of Specialist Medicine, Hull Hospital, Gatineau, QC, Canada.
Chest. 2025 Mar;167(3):736-745. doi: 10.1016/j.chest.2024.09.031. Epub 2024 Oct 9.
COPD inhaler regimens should be appropriate for the patient's peak inspiratory flow (PIF) and should ideally consist of single or similar device(s).
In a subspecialized COPD clinic: (1) What is the prevalence of patients with suboptimal PIF and with inappropriate device(s) for measured PIF? (2) Are there patient-related risk factors associated with suboptimal PIF? (3) What is the prevalence of patients with non-single inhaler therapy (SIT)/nonsimilar devices? (4) Does point-of-care PIF affect clinical decision-making?
In this single-center real-world observational study, PIF was measured systematically at every outpatient visit in a subspecialized COPD clinic, and point-of-care results were provided to the clinician. Coprimary outcomes were the prevalence of outpatients with suboptimal PIF and with inappropriate devices for measured PIF. Secondary outcomes were patient-related risk factors associated with suboptimal PIF, the prevalence of non-SIT/nonsimilar devices, the prevalence of regimens consisting of either inappropriate device(s) for measured PIF and/or non-SIT/nonsimilar devices, and the effect of point-of-care PIF on clinical decision-making.
Suboptimal PIF was identified in 45 of 161 participants (28%), and inappropriate device(s) for measured PIF were identified in 18 participants (11.2%). Significant associations were observed between suboptimal PIF and age (1.09; 95% CI, 1.04-1.15), female sex (10.30; 95% CI, 4.45-27.10), height (0.92; 95% CI, 0.88-0.96), BMI (0.90; 95% CI, 0.84-0.96), and FEV (0.09; 95% CI, 0.03-0.26). After adjustment for age and sex, the association between suboptimal PIF and BMI, but not height, remained significant. Non-SIT and/or nonsimilar devices were identified in 50 participants (31.1%). Regimens consisting of either inappropriate device(s) for measured PIF and/or non-SIT/nonsimilar devices were observed in 59 participants (36.6%). Inhaler prescription changes were observed in this latter group (3.39; 95% CI, 1.76-6.64), as well as in patients with suboptimal PIF who already had SIT/similar regimens (2.93; 95% CI, 1.07-7.92).
Suboptimal PIF and inappropriate devices for measured PIF were highly prevalent among outpatients from a subspecialized COPD clinic. Our results show that female sex, reduced FEV, and low BMI are important, readily identifiable risk factors for suboptimal PIF, and point-of-care PIF can inform clinical decision-making.
慢性阻塞性肺疾病(COPD)吸入治疗方案应适合患者的最大吸气流量(PIF),且理想情况下应由单一或类似装置组成。
在一家专科COPD诊所中:(1)PIF未达最佳水平且所使用装置不适合所测PIF的患者的患病率是多少?(2)是否存在与PIF未达最佳水平相关的患者相关危险因素?(3)非单一吸入器治疗(SIT)/非类似装置的患者患病率是多少?(4)即时检测PIF是否会影响临床决策?
在这项单中心真实世界观察性研究中,在一家专科COPD诊所的每次门诊就诊时系统测量PIF,并将即时检测结果提供给临床医生。共同主要结局是PIF未达最佳水平以及所使用装置不适合所测PIF的门诊患者的患病率。次要结局是与PIF未达最佳水平相关的患者相关危险因素、非SIT/非类似装置的患病率、由所测PIF不适合的装置和/或非SIT/非类似装置组成的治疗方案的患病率,以及即时检测PIF对临床决策的影响。
161名参与者中有45名(28%)的PIF未达最佳水平,18名参与者(11.2%)所使用的装置不适合所测PIF。观察到PIF未达最佳水平与年龄(1.09;95%置信区间,1.04 - 1.15)、女性(10.30;95%置信区间,4.45 - 27.10)、身高(0.92;95%置信区间,0.88 - 0.96)、体重指数(BMI)(0.90;95%置信区间,0.84 - 0.96)和第1秒用力呼气容积(FEV)(0.09;95%置信区间,0.03 - 0.26)之间存在显著关联。在对年龄和性别进行调整后,PIF未达最佳水平与BMI之间的关联仍然显著,但与身高无关。50名参与者(31.1%)使用了非SIT和/或非类似装置。59名参与者(36.6%)的治疗方案由所测PIF不适合的装置和/或非SIT/非类似装置组成。在后一组以及已经采用SIT/类似治疗方案但PIF未达最佳水平的患者中观察到吸入器处方的改变(3.39;95%置信区间,1.76 - 6.64)以及(2.93;95%置信区间,1.07 - 7.92)。
在一家专科COPD诊所的门诊患者中,PIF未达最佳水平以及所使用装置不适合所测PIF的情况非常普遍。我们的结果表明,女性、FEV降低和低BMI是PIF未达最佳水平的重要且易于识别的危险因素,即时检测PIF可为临床决策提供参考。